Bub1 suppresses inflammatory arthritis-associated bone loss in mice through inhibition of TNFα-mediated osteoclastogenesis

Shuhei Yoshida,Aoi Ikedo,Yuta Yanagihara,Tomohisa Sakaue,Noritaka Saeki,Yuuki Imai

DOI: https://doi.org/10.1093/jbmr/zjae015

IF: 6.39

2024-01-27

Journal of Bone and Mineral Research

Abstract:Abstract Rheumatoid arthritis (RA) is an inflammatory autoimmune disease characterized by synovitis, bone and cartilage destruction, and increased fracture risk with bone loss. Although disease-modifying anti-rheumatic drugs (DMARDs) have dramatically improved clinical outcomes, these therapies are not universally effective in all patients due to the heterogeneity of RA pathogenesis. Therefore, it is necessary to elucidate the molecular mechanisms underlying RA pathogenesis, including associated bone loss, in order to identify novel therapeutic targets. In this study, we found that Budding uninhibited by benzimidazoles 1 (BUB1) was highly expressed in RA patients’ synovium and murine ankle tissue with arthritis. As CD45+CD11b+ myeloid cells are a Bub1 highly expressing population among synovial cells in mice, myeloid cell-specific Bub1 conditional knockout (Bub1ΔLysM) mice were generated. Bub1ΔLysM mice exhibited reduced femoral bone mineral density (BMD) when compared to control mice under K/BxN serum-transfer arthritis (STA), with no significant differences in joint inflammation or bone erosion based on a semi-quantitative erosion score and histological analysis. Bone histomorphometry revealed that femoral bone mass of Bub1ΔLysM under arthritis was reduced by increased osteoclastic bone resorption. RNA-seq and subsequent Gene Set Enrichment Analysis (GSEA) demonstrated a significantly enriched NF-κB pathway among up-regulated genes in RANKL-stimulated bone marrow-derived macrophages (BMMs) obtained from Bub1ΔLysM mice. Indeed, osteoclastogenesis using BMMs derived from Bub1ΔLysM was enhanced by RANKL and TNFα or RANKL and IL-1β treatment compared to controls. Finally, osteoclastogenesis was increased by Bub1 inhibitor BAY1816032 treatment in BMMs derived from wildtype mice. These data suggest that Bub1 expressed in macrophages plays a protective role against inflammatory arthritis-associated bone loss through inhibition of inflammation-mediated osteoclastogenesis.

endocrinology & metabolism

What problem does this paper attempt to address?

The problem that this paper attempts to solve is the mechanism of bone loss related to rheumatoid arthritis (RA). Specifically, the researchers found that a protein named Budding uninhibited by benzimidazoles 1 (Bub1) is highly expressed in the synovial tissue of RA patients and in the ankle tissue of arthritic mice. By generating a myeloid - cell - specific Bub1 conditional knockout (Bub1ΔLysM) mouse model, the researchers explored the role of Bub1 in inflammatory - arthritis - related bone loss.

### Research Background
Rheumatoid arthritis is a chronic inflammatory autoimmune disease, characterized by joint synovitis, bone and cartilage destruction, and systemic bone loss. Although biological agents and disease - modifying antirheumatic drugs have significantly improved the clinical treatment effect, due to the heterogeneity of the pathogenesis of RA, these therapies are not effective for all patients. Therefore, it is necessary to clarify the pathogenesis of RA and the molecular mechanism of its related bone loss in order to identify new therapeutic targets.

### Research Methods
1. **Gene Expression Data Analysis**: Analyze the gene expression in the synovial tissue of human RA patients and mouse arthritis models using high - throughput sequencing data sets.
2. **Generation of Bub1 Conditional Knockout Mice**: Generate Bub1 conditional knockout mice through CRISPR - Cas9 technology.
3. **K/BxN Serum - Transfer Arthritis Model**: Induce K/BxN serum - transfer arthritis and evaluate the severity of arthritis and bone loss.
4. **Fluorescence - Activated Cell Sorting**: Isolate synovial cells and detect the expression level of Bub1.
5. **Radiological Examination**: Use dual - energy X - ray absorptiometry (DXA) and micro - computed tomography (μCT) to evaluate bone density and bone structure.
6. **In Vitro Experiments**: Conduct in vitro culture of bone marrow macrophages (BMMs) and osteoblast differentiation experiments, and detect the effect of Bub1 inhibitors on osteoblast differentiation.

### Main Findings
1. **Bub1 is highly expressed in RA synovial tissue and mouse arthritis models**: Especially in myeloid cells.
2. **Bub1ΔLysM mice show lower femoral bone density in the K/BxN serum - transfer arthritis model**: This is mainly due to the increased osteoclast - mediated bone resorption.
3. **RNA - seq and Gene Set Enrichment Analysis**: Reveal significant enrichment of the nuclear factor κB (NF - κB) pathway in BMMs derived from Bub1ΔLysM under RANKL stimulation.
4. **Bub1 Inhibitor Treatment**: Treatment of BMMs derived from wild - type mice with the Bub1 inhibitor BAY1816032 enhances osteoblast differentiation.

### Conclusion
The research results indicate that Bub1 has a protective effect on inflammatory - arthritis - related bone loss in myeloid cells by inhibiting inflammation - mediated osteoclast differentiation. This finding provides a potential molecular target for the development of treatment strategies for RA - related bone loss.